A report of Bell's Palsy triggered by leptomeningeal metastases from recurrent high grade serous ovarian cancer
Publication date: Available online 19 October 2018Source: Gynecologic Oncology ReportsAuthor(s): Khilen B. Patel, Anna Gaidis, Angela Stephens, Thomas Z. Thompson, Heather Williams, Bunja Rungruang (Source: Gynecologic Oncology Reports)
Source: Gynecologic Oncology Reports - October 20, 2018 Category: OBGYN Source Type: research

Neoplastic meningitis: A study from a Tertiary Care Hospital from coastal India
Conclusion: A combined diagnostic approach including biochemical, microbiological and pathological evaluation was useful in eliminating infectious meningitis and confirming neoplastic meningitis in these cases. Cytology should be performed on cerebrospinal specimens from all patients with known or suspected malignancy with meningismus. Detection of malignant cells on cytological examination of CSF is the diagnostic gold standard for neoplastic meningitis. (Source: Journal of Cytology)
Source: Journal of Cytology - October 19, 2018 Category: Cytology Authors: Pooja K Suresh Jyoti Ramanath Kini Sridevi H Basavaiah Hema Kini Urmila N Khadilkar Shrijeet Chakraborti Source Type: research

Osimertinib quantitative and gene variation analyses in cerebrospinal fluid and plasma of non-small cell lung cancer patient with leptomeningeal metastases.
CONCLUSIONS: ctDNA from CSF might be a useful biomarker for monitoring the efficacy of treatment and an effective complement to nuclear magnetic resonance (MRI) for LM. PMID: 30332963 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - October 17, 2018 Category: Cancer & Oncology Authors: Song Y, Liu P, Huang Y, Guan Y, Han X, Shi Y Tags: Curr Cancer Drug Targets Source Type: research

Management of hydrocephalus in patients with leptomeningeal metastases: an ethical approach to decision-making
ConclusionsThe decision of how to manage LM-associated hydrocephalus is complex and requires close collaboration amongst the physician, patient, and/or patient ’s family/friends/community leaders. Ultimately, the decision should be rooted in the patients’ values and should aim to optimize a patient’s quality-of-life. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - October 1, 2018 Category: Cancer & Oncology Source Type: research

Extensive leptomeningeal intracranial and spinal metastases in a patient with a supratentorial glioblastoma multiforme, IDH-wildtype: A case report
Glioblastomas are usually characterized by diffuse, infiltrative growth and local tumor progression. Extensive leptomeningeal metastases are rarely observed. It remains unclear which GBMs are prone to this specific growth pattern/progression and standardized salvage treatment protocols are unavailable. (Source: World Neurosurgery)
Source: World Neurosurgery - September 22, 2018 Category: Neurosurgery Authors: Christoph Schwartz, Alexander Romagna, Lukas Machegger, Lukas Weiss, Florian Huemer, Gerd Fastner, Waltraud Kleindienst, Weis Serge, Richard Greil, Peter A. Winkler Tags: Case Report Source Type: research

Cauda equine syndrome as the primary symptom of leptomeningeal metastases from lung cancer: a case report and review of literature
(Source: OncoTargets and Therapy)
Source: OncoTargets and Therapy - August 20, 2018 Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research

Treatment response to osimertinib in a patient with leptomeningeal metastasis from lung adenocarcinoma following failure of gefitinib and erlotinib: A case report.
Abstract Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are effective in the treatment of advanced non-small-cell lung cancer (NSCLC) with leptomeningeal metastases (LM); however, a proportion of the patients with resistant tumors do not benefit from EGFR-TKI treatment. In the present study the case of a female patient with advanced lung adenocarcinoma harboring the EGFR L858R mutation (encoded in exon 21) who developed intracranial metastases following treatment with erlotinib after gefitinib failure is reported. The patient achieved a partial response (PR) after four cycles of ch...
Source: Clinical Lung Cancer - August 17, 2018 Category: Cancer & Oncology Authors: Li J, Liu X, Yuan C Tags: Mol Clin Oncol Source Type: research

Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
CONCLUSION: Despite being limited by their retrospective nature, these results highlight the need for clinical trials in BC LMD, stratified on tumor biology. IMPLICATIONS FOR PRACTICE: Leptomeningeal disease (LMD) is a devastating complication of breast cancer (BC), and its optimal therapy is still not defined. Here, patient characteristics, treatment patterns, and prognostic factors from a contemporary cohort of 153 BC-related LMD patients are reported. In multivariate analysis, Eastern Cooperative Oncology Group performance status, cerebrospinal fluid glucose levels, and having received systemic treatment were co...
Source: The Oncologist - August 17, 2018 Category: Cancer & Oncology Authors: Griguolo G, Pouderoux S, Dieci MV, Jacot W, Bourgier C, Miglietta F, Firmin N, Conte P, Viala M, Guarneri V, Darlix A Tags: Oncologist Source Type: research

An Acquired Epidermal Growth Factor Receptor T790M Mutation after the Addition of Bevacizumab to Preceding Erlotinib Monotherapy in a Lung Cancer Patient with Leptomeningeal Metastases.
Authors: Tsuchiya K, Karayama M, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Inui N, Suda T Abstract A 53-year-old man with advanced lung adenocarcinoma harboring epidermal growth factor receptor (EGFR) exon 19 deletion received erlotinib. After 12 months of disease control with erlotinib monotherapy, leptomeningeal metastases (LM) occurred. A cerebrospinal fluid examination demonstrated a pre-existing EGFR exon 19 deletion. Bevacizumab was combined with erlotinib, and the LM improved. After six months of combination therapy, however, the LM was exacerbated. A re-examinatio...
Source: Internal Medicine - August 15, 2018 Category: Internal Medicine Tags: Intern Med Source Type: research

Non-small cell lung cancer leptomeningeal metastases treated with intrathecal therapy plus osimertinib and temozolomide and whole-brain radiation therapy: a case report
(Source: OncoTargets and Therapy)
Source: OncoTargets and Therapy - August 10, 2018 Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research

Efficacy of Osimertinib in EGFR -Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors
ConclusionsIn this non-selected population, osimertinib had remarkable efficacy in NSCLC patients with LM irrespective of the presence of theEGFR-T790M –resistance mutation. Osimertinib efficacy was rapid in several patients, even some with poor performance status. (Source: Targeted Oncology)
Source: Targeted Oncology - August 1, 2018 Category: Cancer & Oncology Source Type: research

Great efficacy of bevacizumab plus erlotinib for leptomeningeal metastases from non-small cell lung cancer with initially positive EGFR mutation: a case report.
We present the case of a 52-year-old female non-smoker with advanced lung adenocarcinoma and initially positive EGFR-mutation, who failed to the treatment of standard first-line chemotherapy (pemetrexed plus cisplatin) and bevacizumab (BEV), and maintenance therapy with pemetrexed plus BEV. Under the progression-free survival of 6 months, suffered from LMs, then erlotinib combined with BEV were delivered, and symptoms were significantly alleviated, remained stable and even relieved slightly for at least 18 months. The combination of bevacizumab and erlotinib could be an optional effective management strategy for patients...
Source: Cancer Biology and Therapy - August 1, 2018 Category: Cancer & Oncology Authors: Jing W, Wang H, Kong L, Yu J, Zhu H Tags: Cancer Biol Ther Source Type: research

Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer
Ana Turkaj, Anna M. Morelli, Tiziana Vaval à, Silvia Novello (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - July 27, 2018 Category: Cancer & Oncology Source Type: research

Efficacy of Osimertinib in EGFR -Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors
ConclusionsIn this non-selected population, osimertinib had remarkable efficacy in NSCLC patients with LM irrespective of the presence of theEGFR-T790M –resistance mutation. Osimertinib efficacy was rapid in several patients, even some with poor performance status. (Source: Targeted Oncology)
Source: Targeted Oncology - July 23, 2018 Category: Cancer & Oncology Source Type: research